Affymax does not believe the promises in the ‘078 patent are valid. Even in the event that claims of the patent were discovered to end up being valid, Affymax believes that they do not encompass Hematide. The ‘078 patent purports to cover methods of dimerizing and activating the EPO receptor using covalently linked peptide monomers which usually do not activate the EPO receptor unless dimerized. Affymax asserts that Hematide will not infringe any of the claimed methods described in the ‘078 patent.. Affymax receives arbitration panel decision linked to dispute against JNJ subsidiaries Affymax, Inc. today announced that it offers received a decision from the arbitration panel reviewing its dispute against certain subsidiaries of Johnson and Johnson . The panel has determined that Affymax and JNJ are co-owners of particular intellectual property, including U.S.Based on this study, giving out free nicotine patches and more intensive telephone counselling through the English nationwide quitline just doesn’t seem to function. It brings into sharpened relief the necessity to find different ways of using quitlines help smokers give up and so to lessen the terrible effects cigarette smoking has on people’s lives and the pricey burden to the NHS. Smoking remains the single most important avoidable reason behind illness and death and research into smoking cessation is usually a top public health priority in the united kingdom. This latest research by UKCTCS attempt to compare the effectiveness of a package of extra support offered to smokers with the typical support offered through the English NHS Smoking cigarettes Helpline.